Programmable Implantable Medication System: Its Applications to Diabetes

摘要

In Year 03, animal work has continued to lay the basis for human implantation of the Implantable, Programmable Infusion Pump (IPIP), the implanted component of PIMS. The authors did not progress to the point of human implantation because technical obstacles were not solved to their satisfaction. Specifically, the ability to avoid bubbling of solution in the reservoir remains inadequate. Progress has been made in other areas, notably in delivery catheter design, the use of different insulin concentrations from n-100 to n-400, and the avoidance of insulin aggregation problems. The authors have, now, longevity experience with two IPIPS: one was implanted for 18 months before a known-to-be-temporary electronic chip failed; the second is still operational after 20 months, not having a temporary chip. The experience is encouraging. The authors have also pursued specific site projects, and completed a study of hepatic triglyceride lipase in well controlled vs. poorly controlled diabetic dogs.